final .cdr

ACKNOWLEDGEMENT
The authors are thankful to Manager, Medrich
Pharmaceuticals, Bangalore for providing facilities to do this
work
REFERENCES
NK Sathish et al Visible Spectro Photometric Determination of Darifenacin Hydrobromide in bulk and Pharmaceutical dosage forms
1. Bulmer P, Abrams P. The overactive bladder. Review of
contemporary Pharmacotherapy. 2000; 11(1): 1-11.
2. Abrams P, Lardozo L, Fall M et al., The standerdisation of
terminology in lower urinary track function: Report from the
standardization subcommittee of the international
continence society. Neuro urol Urodyn. 2002; 21: 167-78.
48
3. Robert ML, Yung SJ. Catherine W et al., A model of bladder
instability to compare the effectiveness of Darifenacine
Hydrobromide at inhibiting over active bladder (OAB)
dysfunction in both male and female Rabbits. International
Urology and Nephrology. 2008; 40(2); 303-09.
4. Napier C, Gupta P. Darifenacin is selective for the human
recombinant M receptor subtype. Neuroural Urodyn. 2001;
3
20: A445.
Address for Correspondence:
Dr. N.K. Sathish, Professor, Dept. of Pharmaceutical Chemistry, SAC College
of Pharmacy, BG Nagara - 571 448, Mandya Dt., Karnataka, India.
E-mail : nksathish76@rediffmail.com
RJPS, Apr-Jun, 2011/ Vol 1/ Issue 1